Metoprolol tartrate is a short-acting beta-blocker prescribed primarily to lower blood pressure, treat chest pain from coronary artery disease, and protect the heart after a heart attack. It works by blocking beta-1 receptors on the heart, which slows heart rate and reduces how forcefully the heart contracts. Because the tartrate salt is absorbed and cleared relatively quickly, it is typically dosed two or three times a day, which distinguishes it from its close relative, metoprolol succinate, designed for once-daily dosing. Understanding the practical differences between the two formulations, the side effects that catch people off guard, and the drug interactions that can turn a standard dose into something much stronger is worth more than most patients realize.
How It Works at the Receptor Level
Beta-blockers dampen the effects of adrenaline (epinephrine) and noradrenaline (norepinephrine) on the heart. Metoprolol tartrate is classified as beta-1 selective, meaning it preferentially blocks the beta-1 receptors concentrated in heart tissue rather than the beta-2 receptors found in the lungs and blood vessels. This selectivity is why it is generally considered safer than older, non-selective beta-blockers for people with mild airway disease, though the selectivity is dose-dependent and starts to fade at higher doses.
One quirk of beta-1 selective blockers is what they do to the body’s sympathetic signaling. When researchers compared intravenous metoprolol to the non-selective beta-blocker propranolol in patients with heart failure, both drugs slowed the heart rate by similar amounts. But cardiac norepinephrine spillover actually increased after metoprolol, while it decreased after propranolol. In other words, by blocking only beta-1 receptors, metoprolol leaves the beta-2 pathways open, and the body’s sympathetic nervous system compensates by ramping up local norepinephrine release around the heart.1PubMed. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure This does not cancel out the drug’s benefit, but it helps explain why some patients on metoprolol still feel palpitations or why dose adjustments are sometimes needed.
Long-term use of metoprolol also causes the body to upregulate beta-receptor density on heart cells, essentially growing more receptors to compensate for the ones being blocked.2European Journal of Heart Failure. Differing Beta-Blocking Effects of Carvedilol and Metoprolol This receptor upregulation is clinically important when the drug is stopped, as those extra receptors suddenly become unblocked and hypersensitive to circulating adrenaline. That is the biological basis for the rebound effect discussed later in this article.
Tartrate Versus Succinate
These are not two different drugs. They are two salt forms of the same active molecule, but the difference in how they behave in the body is significant enough that they are not freely interchangeable. Metoprolol tartrate is inherently short-acting, with an elimination half-life of roughly four to five hours, so it washes out of the bloodstream relatively fast. Metoprolol succinate, by contrast, is formulated as an extended-release tablet designed to deliver the drug steadily over 24 hours.3PubMed. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure
This pharmacokinetic difference has real clinical consequences. In a multicenter study comparing heart failure outcomes between the two formulations, patients on metoprolol succinate had a lower rate of the combined endpoint of hospitalizations and death than those on metoprolol tartrate (about 29% versus 34%). Event-free survival was also higher in the succinate group.4Journal of Cardiac Failure – Intersections. Differential Impact of Metoprolol Formulations on Heart Failure Outcomes: A Multicenter Study The reasons likely include more consistent blood levels throughout the day and fewer peaks and troughs in beta-blockade. For heart failure specifically, current guidelines lean toward the succinate formulation. But for acute situations, immediate blood pressure reduction, or settings where you want a drug that clears the system quickly, the tartrate form has advantages.
People sometimes switch between the two without understanding that the total daily dose does not convert one-to-one. A cardiologist adjusting from tartrate to succinate typically recalculates the dose based on the different release profiles. If your pharmacy hands you a different-looking metoprolol bottle, it is worth confirming which salt form you are getting.
Lowering Blood Pressure
Hypertension was one of the original indications for metoprolol, and it remains among the most common reasons it is prescribed. In an early pharmacokinetic study, a single 80 mg dose of metoprolol tartrate lowered systolic blood pressure from about 167 to 146 mmHg, and with continued dosing at steady state the drop settled at roughly 160 to 140 mmHg. A 50 mg dose showed a smaller but still meaningful reduction.5PubMed Central. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment Both doses also markedly reduced heart rate, which is the more immediately noticeable effect for most patients.
Beta-blockers as a class have fallen somewhat out of favor as first-line hypertension drugs compared with calcium channel blockers and ACE inhibitors, but metoprolol tartrate remains a reasonable choice when a patient also has a fast resting heart rate, a history of heart attack, or certain arrhythmias. The short half-life means blood pressure coverage can dip between doses, so twice-daily dosing is the minimum for most people.
Angina and Heart Attack Protection
For people with stable angina, metoprolol tartrate reduces how often chest pain episodes occur and how much nitroglycerin they need. In a controlled trial comparing it with propranolol, both drugs lowered resting and exercise heart rates and significantly improved exercise tolerance on a bicycle ergometer. Neither drug lowered blood pressure at rest, but both reduced it during exercise, which is when angina typically strikes.6PubMed. Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris The takeaway is that metoprolol performs comparably to its non-selective predecessor for angina relief while carrying fewer respiratory side effects.
The drug’s role during an acute heart attack is more dramatic. In the METOCARD-CNIC trial, patients experiencing a large heart attack who received intravenous metoprolol before the artery was reopened had better heart pump function at six months compared with controls. Their average ejection fraction was about 49% versus 45%, and the rate of severely depressed heart function dropped from 27% in the control group to 11% in the metoprolol group. At two years of follow-up, hospital admissions for heart failure were significantly lower in those who received early metoprolol.7PubMed. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial The idea is that slowing the heart and reducing oxygen demand during the critical window limits the size of the damage zone.
Rate Control in Atrial Fibrillation
When the heart’s upper chambers start firing chaotically in atrial fibrillation, the immediate priority is usually to slow the ventricular rate. Beta-blockers have historically been among the most commonly selected agents for this purpose.8PubMed Central. A Systematic Review of Weight-Based Metoprolol for Acute Atrial Fibrillation with Rapid Ventricular Rate Intravenous metoprolol is frequently the first drug pushed in an emergency department when someone arrives with a racing heart from new-onset atrial fibrillation.
How does it stack up against the calcium channel blocker diltiazem, its main competitor in that setting? In a retrospective comparison, rate control was achieved in about 35% of the metoprolol group versus 41% of the diltiazem group, with no statistically significant difference. The average time to rate control was 35 minutes for metoprolol versus 21 minutes for diltiazem, again not reaching statistical significance.9PubMed. Intravenous Metoprolol Versus Diltiazem for Rate Control in Atrial Fibrillation In practice, clinicians often choose between them based on the patient’s other conditions. Metoprolol gets the nod when the patient also has coronary disease or heart failure with preserved ejection fraction. Diltiazem is avoided in patients with severely reduced pump function.
How the Liver Processes Metoprolol
Metoprolol tartrate is almost entirely cleared by the liver, which means kidney function matters surprisingly little. A study comparing patients with varying degrees of renal impairment to healthy controls found no significant differences in bioavailability, clearance, or half-life. The oral bioavailability at steady state was about 59% in those with kidney problems and 55% in controls, and the elimination half-life hovered around four to five hours in both groups.10PubMed. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function So unlike many cardiac drugs, metoprolol tartrate generally does not need dose adjustment in people on dialysis or with chronic kidney disease. Liver disease, on the other hand, can substantially slow clearance and raise drug levels.
The specific liver enzyme responsible for breaking down metoprolol is CYP2D6, and this is where genetics become relevant. The CYP2D6 gene is notoriously variable across the population. People who carry gene variants that produce little or no functional enzyme, known as poor metabolizers, clear the drug much more slowly and end up with higher blood concentrations at the same dose. In one study, there was a 36-fold difference between the highest and lowest clearance values across different CYP2D6 genotypes, with the highest metoprolol levels per unit dose found in a patient homozygous for the CYP2D6*4 variant.11PubMed. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients
In clinical terms, the heart rate response to metoprolol differs significantly by CYP2D6 phenotype, with poor and intermediate metabolizers showing a greater heart rate reduction. Blood pressure response and adverse-effect rates, however, did not differ significantly by genotype in one large analysis.12PubMed Central. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate So your genetic makeup can influence how much the drug slows your heart, but it does not reliably predict whether you will get dizzy or drop your blood pressure too low. Pharmacogenomic testing for CYP2D6 exists, and some institutions use it, but it has not become routine before prescribing metoprolol.
Drug Interactions That Effectively Multiply the Dose
Because CYP2D6 is the primary pathway for metabolizing metoprolol, any drug that inhibits this enzyme can dramatically increase metoprolol levels. The most clinically important example is paroxetine, a widely prescribed antidepressant. When paroxetine is taken alongside metoprolol tartrate, the area under the curve for metoprolol increases by roughly four- to five-fold. Systolic blood pressure and heart rate drop significantly more than with metoprolol alone.13PubMed Central. The impact of CYP2D6 mediated drug–drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine In pharmacokinetic terms, paroxetine essentially converts an extensive metabolizer into the functional equivalent of a poor metabolizer.
The interaction also disrupts the normal stereoselective metabolism of metoprolol, meaning the drug loses some of its beta-1 selectivity. Paroxetine inhibition leads to a greater increase in the R-enantiomer of metoprolol, which is the less cardioselective form, theoretically increasing the potential for beta-2 effects like airway constriction.14Journal of Clinical Pharmacology. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine This interaction applies to the extended-release succinate form as well, though the magnitude is slightly smaller.
Paroxetine is not the only culprit. Fluoxetine (Prozac), amiodarone, celecoxib, cimetidine, terbinafine, and diphenhydramine (the active ingredient in many over-the-counter sleep aids) have all been shown to raise metoprolol levels.15PubMed. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview If you have been stable on metoprolol and a new medication is added, a heart rate that drops unusually low or new-onset fatigue and dizziness could signal a drug interaction rather than progression of your underlying condition.
Side Effects and Why Sleep Suffers
In a survey of heart failure patients taking beta-blockers, the most frequently reported side effects were weight gain (59%), fatigue (56%), dizziness (41%), and shortness of breath (29%). Among those who had to stop the medication entirely, fatigue and low blood pressure were the most common reasons.16Journal of Cardiac Failure. Tolerability of Beta-Blockers in Heart Failure These numbers reflect beta-blockers as a class in heart failure patients, who tend to be more symptomatic than the general hypertension population, but fatigue in particular is a complaint across the board.
Sleep disruption deserves special attention because it often goes unrecognized. Metoprolol is moderately lipophilic, meaning it dissolves in fat and can cross into the brain more readily than water-soluble beta-blockers like atenolol.17Pharmacology. Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples In a study comparing several beta-blockers against placebo, metoprolol users averaged about 7.2 awakenings per night compared to 3.9 with placebo and 3.6 with the water-soluble beta-blocker atenolol. Time spent awake after falling asleep was roughly double the placebo level. Subjective reports matched the objective data, with people on lipophilic beta-blockers describing more restlessness and difficulty staying asleep.18PubMed. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties If you started metoprolol and your sleep quality tanked, the drug is a likely contributor, and switching to a more hydrophilic beta-blocker like atenolol is a conversation worth having with your prescriber. Vivid dreams and nightmares are also commonly reported, likely related to the same CNS penetration.
What Happens When You Stop Abruptly
The receptor upregulation mentioned earlier explains why you should never stop metoprolol tartrate cold turkey. After withdrawal, studies have documented a roughly 52% average rebound increase in the heart’s sensitivity to adrenergic stimulation, along with a 15% rise in resting heart rate, beginning two to eight days after the last dose.19PubMed. Metoprolol withdrawal phenomena: mechanism and prevention This rebound is not just uncomfortable. In patients with coronary artery disease, the sudden surge in heart rate and contractility can provoke angina or, in extreme cases, trigger a heart attack. Tapering over one to two weeks is standard practice for exactly this reason.
The short half-life of the tartrate form may make it slightly more prone to inter-dose withdrawal effects compared to the extended-release succinate, though both require gradual tapering. If you miss a dose of tartrate and your next one is not far off, take it as soon as you remember. If it is close to the next scheduled dose, skip the missed one rather than doubling up.
Airway Concerns and Asthma
The beta-1 selectivity of metoprolol provides some safety margin for people with mild reactive airway disease, but that margin has limits. A review of studies found that metoprolol and atenolol were generally well tolerated in asthmatic patients with hypertension, except at higher doses such as metoprolol above 100 mg daily, where beta-2 blockade starts to become clinically relevant.20PubMed. Cardioselective beta-blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks? Moderate to severe asthma remains a relative contraindication, and even mild asthmatics should be monitored when starting or increasing the dose. The CYP2D6 interaction issue makes this even more complex: if a strong CYP2D6 inhibitor raises metoprolol levels substantially, the effectively higher dose could push beta-2 blockade past the safety threshold in someone whose lungs were fine on the original dose.
Essential Tremor and Other Off-Label Uses
Propranolol is the traditional beta-blocker for essential tremor, but metoprolol tartrate is a reasonable alternative when propranolol cannot be used. In a double-blind crossover trial, metoprolol reduced tremor magnitude by about 47%, compared with about 55% for propranolol, a difference that was not statistically significant.21PubMed Central. Metoprolol and propranolol in essential tremor: a double-blind, controlled study In a separate trial, metoprolol improved tremor in 13 of 23 patients, including three patients with asthma in whom propranolol had caused respiratory distress.22PubMed. Metoprolol compared with propranolol in the treatment of essential tremor So for people who need tremor control but cannot tolerate a non-selective beta-blocker due to lung disease, metoprolol tartrate fills a genuine niche.
Performance anxiety and situational tachycardia are other common off-label uses. Metoprolol tartrate’s short duration of action makes it appealing for one-off situations, since the effect largely wears off within several hours. Migraine prophylaxis is another well-established off-label indication for beta-blockers generally, though the evidence base is stronger for propranolol and the succinate formulation of metoprolol than for the tartrate form.
Overdose and Emergency Management
Beta-blocker overdose is a medical emergency. Metoprolol’s lipophilicity and direct myocardial depressant effects mean that large ingestions can rapidly produce severe slowing of the heart, dangerously low blood pressure, and cardiovascular collapse. A published case report described a patient who intentionally ingested roughly 7.5 grams of metoprolol tartrate and developed cardiac arrest despite initial treatment with glucagon, atropine, and vasopressors. He was ultimately resuscitated with intravenous lipid emulsion and high-dose insulin with glucose support.23PubMed. Successful treatment of a massive metoprolol overdose using intravenous lipid emulsion and hyperinsulinemia/euglycemia therapy Glucagon has traditionally been the go-to antidote for beta-blocker poisoning, but high-dose insulin therapy and lipid emulsion have emerged as important rescue strategies when conventional treatments fail.
Perioperative Use and Stroke Risk
A controversial area of metoprolol use is the perioperative setting. Giving beta-blockers before and during surgery was once widely promoted to prevent cardiac complications. But a large retrospective analysis found that preoperative metoprolol was associated with an approximately 4.2-fold increase in perioperative stroke compared to patients on other beta-blockers. When matched against patients taking atenolol specifically, the metoprolol group had a significantly higher stroke incidence. Intraoperative metoprolol was associated with a 3.3-fold increase in perioperative stroke, while no such association was found for intraoperative esmolol or labetalol.24PubMed. Perioperative metoprolol and risk of stroke after noncardiac surgery
The reasons remain debated. Metoprolol’s lipophilicity and the abrupt hemodynamic swings that can come from its short-acting pharmacokinetics during the stress of surgery are plausible contributors. This does not mean metoprolol should never be used around the time of surgery, but it does mean anesthesiologists increasingly prefer longer-acting or less lipophilic beta-blockers in that context. If you are on metoprolol tartrate and heading into a non-cardiac surgery, your surgical team will likely want to discuss whether to continue it, switch agents, or adjust timing relative to the procedure.